84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy
| Autor: | Eugene Wright, Eden Miller, Laura Brandner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty endocrine system diseases business.operation business.industry Long acting insulin Abbott Laboratories Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment nutritional and metabolic diseases 030209 endocrinology & metabolism Pharmacy Type 2 diabetes medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Internal medicine Diabetes mellitus Cohort Internal Medicine medicine Claims database business |
| Zdroj: | Diabetes. 69 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | Data for patients with type 2 diabetes (T2D) on long-acting insulin (LAI) or non-insulin therapy using continuous glucose monitors is limited. This study evaluates change in HbA1c from baseline to 6mo and baseline to 12mo after starting a FreeStyle Libre system for T2D patients on LAI and non-insulin (including GLP-1) therapy. A retrospective, observational analysis was performed by linking data from the LibreView® data management platform, DRG (a commercial medical and pharmacy claims database), and Quest lab HbA1c. Only deidentified data was used for analysis. Index was the first date of data in LibreView (Nov 2017-Sept 2019). Medication and diagnosis were from DRG. HbA1c tests were from Quest. Baseline A1c must be ≥ 6.5% within 6mo prior to index. HbA1c tests closest to +180 days (+150-210) used for 6mo; closest to +360 days (+330-390) used for 12mo. The 6mo T2D cohort (n=774) reduced HbA1c by -0.8%. The 12mo T2D cohort (n=207) reduced HbA1c by -0.6%. The greatest reduction in HbA1c was seen in the T2D non-insulin group at 6mo (-0.9%, n=497) and 12mo (-0.7% n=120). All groups saw clinically significant reduction in HbA1c (Table). Reduction in HbA1c post-FreeStyle Libre use supports the real-world effectiveness of the system in T2D patients using long-acting insulin or non-insulin therapies. Disclosure E. Miller: None. L. Brandner: Employee; Self; Abbott Laboratories. E. Wright: Advisory Panel; Self; Abbott, Sanofi. Consultant; Self; Abbott, AstraZeneca, Bayer U.S., Boehringer Ingelheim Pharmaceuticals, Inc., MannKind Corporation, Merck & Co., Inc., Voluntis France. Speaker’s Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|